Kanał ELOX
EL

Eloxx Pharmaceuticals, Inc.

ELOX · NASDAQ

$17.45 -8.06% (-$1.53)
1M -2.72%
Market Cap $314.0
P/E Ratio -
Div. Yield -
ROE -
Piotroski F-Score Weak
3/9
Valuation
-
N/A
P/E N/A
EV/EBITDA N/A
P/S N/A
Growth
-
N/A
EPS growth N/A
Rev. growth N/A
FCF growth N/A
Profitability
-
N/A
Gross margin N/A
Net margin N/A
Op. margin N/A
Quality
0 /100
Poor
ROIC 1,263.55%
ROA 170.74%
Asset turnover 0.00x
Debt
56 /100
Moderate
Current ratio 0.87x
Int. coverage -16.64x
Net debt/EBITDA 0.18x
Stability
44 /100
Moderate
Beta -9.95x
EPS volatility 34.31%
Profitable years 0

Bulios Scoring opisuje jakość i historię firmy, a nie przyszły zwrot. Wysoki wynik to nie sygnał zakupu. Dowiedz się więcej

Zapytaj StockBota o ELOX
Online

O spółce

Eloxx Pharmaceuticals, Inc. (ELOX) is a biotechnology company specializing in the development of therapeutic therapies for genetic diseases and rare conditions. The company focuses on developing drug products that can correct genetic mutations and provide treatment for patients suffering from genetic disorders. Eloxx Pharmaceuticals targets the treatment of rare diseases such as cystic fibrosis, Duchenne muscular dystrophy, and other genetic disorders. With the growing awareness of the need for genetic disease treatment, Eloxx Pharmaceuticals, Inc. has the potential for sustained growth. Eloxx Pharmaceuticals, Inc. (ELOX) shares might be an interesting choice for investors seeking involvement in the biotechnology and therapeutic therapies for genetic diseases.

Opis nie jest jeszcze dostępny w Twoim języku, więc tekst jest po angielsku.

Sector

Healthcare

Industry

Biotechnology

CEO

Sumit Aggarwal

Employees

10

Headquarters

Watertown

Nadchodzące wydarzenia

11 LIS

Earnings

Upcoming earnings report

53d

Używamy niezbędnych plików cookie do działania strony oraz opcjonalnych analitycznych plików cookie do pomiaru ruchu. Zobacz naszą Politykę prywatności.